WellBeing International

WBI Studies Repository
2008

Non-Animal Methodologies within Biomedical Research and
Toxicity Testing
Andrew Knight
Animal Consultants International

Follow this and additional works at: https://www.wellbeingintlstudiesrepository.org/acwp_arte
Part of the Bioethics and Medical Ethics Commons, Laboratory and Basic Science Research
Commons, and the Research Methods in Life Sciences Commons

Recommended Citation
Knight, A. (2008). Non-animal methodologies within biomedical research and toxicity testing. Altex, 25(3),
213-231.

This material is brought to you for free and open access
by WellBeing International. It has been accepted for
inclusion by an authorized administrator of the WBI
Studies Repository. For more information, please contact
wbisr-info@wellbeingintl.org.

Non-Animal Methodologies within
Biomedical Research and Toxicity Testing
Andrew Knight

Animal Consultants International, London, UK
Summary
Laboratory animal models are limited by scientific constraints on
human applicability, and increasing regulatory restrictions, driven
by social concerns. Reliance on laboratory animals also incurs
marked – and in some cases, prohibitive – logistical challenges,
within high-throughput chemical testing programmes, such as those
currently underway within Europe and the US. However, a range of
non-animal methodologies is available within biomedical research
and toxicity testing. These include: mechanisms to enhance the
sharing and assessment of existing data prior to conducting further
studies, and physicochemical evaluation and computerised modelling, including the use of structure-activity relationships and expert
systems. Minimally-sentient animals from lower phylogenetic orders or early developmental vertebral stages may be used, as well
as microorganisms and higher plants. A variety of tissue cultures,
including immortalised cell lines, embryonic and adult stem cells,
and organotypic cultures, are also available. In vitro assays utilising
bacterial, yeast, protozoal, mammalian or human cell cultures exist
for a wide range of toxic and other endpoints. These may be static or
perfused, and may be used individually, or combined within test batteries. Human hepatocyte cultures and metabolic activation systems
offer potential assessment of metabolite activity and organ-organ
interaction. Microarray technology may allow genetic expression
profiling, increasing the speed of toxin detection, well prior to more
invasive endpoints. Enhanced human clinical trials utilising microdosing, staggered dosing, and more representative study populations
and durations, as well as surrogate human tissues, advanced imaging modalities and human epidemiological, sociological and psychological studies, may increase our understanding of illness aetiology
and pathogenesis, and facilitate the development of safe and effective
pharmacologic interventions. Particularly when human tissues are
used, non-animal models may generate faster, cheaper results, more
reliably predictive for humans, whilst yielding greater insights into
human biochemical processes. Greater commitment to their development and implementation is necessary, however, to efficiently meet
the needs of high-throughput chemical testing programmes, important emerging testing needs, and the ongoing development of human
clinical interventions.

Zusammenfassung: Versuchstierfreie Methoden in der biomedizinischen Forschung und Toxizitätsprüfung
Tierversuche werden durch wissenschaftliche Einschränkungen und
wachsende regulatorische Restriktionen, welche durch soziale Bedenken angetrieben werden, limitiert. Die Abhängigkeit von Labortieren
führt auch zu deutlichen – und in manchen Fällen prohibitiven – logistischen Herausforderungen innerhalb von Hochdurchsatztestverfahren, wie sie momentan in Europa und den USA durchgeführt werden. Dennoch steht eine Ansammlung von tierfreien Methoden für die
biomedizinische Forschung und die Toxizitätsprüfung zur Verfügung.
Diese schließt ein: Mechanismen, welche die Einsicht und Bewertung
von vorliegenden Daten vor der Durchführung neuer Studien fördern
können, und physikochemische Analysen und Computer-gestützte Modellierung, einschließlich Struktur-Wirkungs-Beziehungen und Expertensystemen. Minimal empfindungsfähige Tiere niederer phylogenetischer Ordnungen oder früher Entwicklungsstadien von Vertebraten
können genutzt werden, sowie Mikroorganismen und höhere Pflanzen.
Eine Vielfalt an Gewebekulturen, einschließlich immortalisierter Zelllinien, embryonaler und adulter Stammzellen und organotypischer
Kulturen stehen zur Verfügung. In vitro Tests, welche auf Kulturen von
Bakterien-, Hefe-, Protozoen-, Säuger- oder menschlichen Zellen beruhen, sind für die Erfassung einer breiten Palette toxischer oder anderer Endpunkte entwickelt worden. Diese Kulturen können statisch oder
perfundiert sein und können individuell oder in Kombination innerhalb
von Testbatterien durchgeführt werden. Humane Hepatozytenkulturen
und metabolische Aktivierungssysteme bieten die Möglichkeit, auch
die Aktivität der Metaboliten zu untersuchen. Die Microarray-Technologie könnte die Erfassung genetischer Expressionsmuster erlauben,
wodurch die Erkennung von Toxinen schneller erfolgen könnte, bereits
vor der Erfassung invasiver Endpunkte. Ausgefeilte klinische Studien
am Menschen, welche von Mikrodosierung, abgestufter Dosierung und
besser repräsentativen Kohorten und Studiendauern sowie von Surrogatgeweben Gebrauch machen, aktuelle bildgebende Verfahren und
epidemiologische, soziologische und psychologische Studien am Menschen könnten unser Verständnis der Ätiologie von Erkrankungen und
ihrer Pathogenese erweitern und die Entwicklung von sicheren und
wirkungsvollen pharmakologischen Interventionen erleichtern. Insbesondere könnten durch Nutzung menschlicher Zellen und Gewebe in
tierfreien Modellen schneller und billiger Ergebnisse erzielt werden,
welche verlässlicher die Wirkung im Menschen vorhersagen könnten,
während sie neue Einsichten in menschliche biochemische Prozesse
liefern würden. Eine stärkere Verpflichtung zur Entwicklung und Implementierung solcher Modelle ist jedoch von Nöten, um effizient die
Anforderungen von Hochdurchsatz-Chemikalientestprogrammen, neu
entstehenden Testbedürfnissen und der Entwicklung klinischer Interventionen zu decken.
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1 Introduction
1.1 Limitations incurred by
animal models
1.1.1 Logistical limitations

Worldwide, millions of animals have been
used in toxicity testing and biomedical research aimed at developing cures for human diseases. Based on publication rates,
Taylor and colleagues (2008) estimated
that 58.3 million living non-human vertebrates were subjected to fundamental or
medically-applied biomedical research,
toxicity testing, or educational use, within 179 countries, in 2005. When animals
killed for the provision of experimental tissues, used to maintain established
genetically-modified strains, or bred for
laboratory use but killed as surplus to requirements, were included, the estimate
increased to a total of approximately 127
million non-human vertebrates worldwide (Knight, 2008). Due to several factors, however, these estimates were considered to be highly conservative.
Additionally, large increases in laboratory animal use have recently been proposed within several chemical testing
programmes intended to rectify knowledge gaps regarding the toxicity of chemicals produced or imported into Europe
or the United States in particularly high
quantities, or that otherwise raise special
concerns (Combes et al., 2004; Green and
Goldberg, 2004). Such programmes follow increasing public, political and regulatory concern about the potential toxicity
of a wide range of environmental, occupational and consumer chemicals.
Prominent among these programmes
is the 2003 Commission of the European
Communities (EC) proposal for the Registration, Evaluation and Authorisation of
Chemicals (REACH), which entered into
force on 1st June, 2007. REACH aims to
assess the toxicity of some 30,000 chemicals produced or imported into the European Union (EU) in excess of one metric
ton annually (Fenner-Crisp et al., 2000;
Green et al., 2001; Charles, 2004; Stokes,
2004; Louekari et al., 2006).
The testing requirements of REACH
are unprecedented. Reproductive and developmental toxicity data, for example,
are required for all substances manufac-
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tured or imported in quantities in excess
of 10 metric tons annually. It has been estimated that reliance on traditional whole
animal testing could require the use of almost 22 million vertebrate animals to meet
such data requirements, at a cost of up to
several hundred thousand dollars per registered substance – although total animal
numbers may reportedly be reduced to 10
million or lower, if proprietary in-house
toxicity data and appropriate non-animal
testing and evaluation methodologies are
utilised (Scialli, 2008).
Within the US, two noteworthy programmes have been managed by the Environmental Protection Agency (EPA)
since 1998. The High Production Volume (HPV) Challenge Programme targets chemicals produced or imported in
quantities in excess of 1 million pounds
annually. As of June 2007, data on 4,460
chemicals had been supplied or was being gathered (EPA, 2008). The Endocrine Disrupting Chemicals Research
Program (EDCs Research Program)
aims to assess dietary and environmental chemicals with the potential to disrupt the normal hormonal milieu within
humans and wildlife. In 1998, the EPA’s
Endocrine Disruptor Screening and Testing Advisory Committee recommended a
tiered testing approach for the evaluation
of oestrogen, androgen and thyroid-related effects of some 87,000 commercial
chemicals and environmental contaminants (Charles, 2004).
The logistical challenges incurred
through reliance on traditional animal
bioassays to meet such unprecedented
testing demands are aptly demonstrated
by the traditional rodent carcinogenicity
bioassay. This assay takes upwards of two
years to produce results of demonstrably
poor human specificity (Knight, et al.,
2006b), at an average cost of € 780,000
(Fleischer, 2007; see also Combes et al.,
2007). Unsurprisingly, by 1998, only
about 2,000 (2.7%) of the 75,000 industrial chemicals then in use and listed
within the EPA Toxic Substances Control
Act inventory had been tested for carcinogenicity (Epstein, 1998). The resources
consumed by testing just these 2.7% of
industrial chemicals included hundreds
of millions of US dollars (Conolly et al.,
1988), millions of skilled personnel hours

(Gold et al., 1999), and millions of animal lives (Monro and MacDonald, 1998;
Gold et al., 1999).
As stated by Bremer and colleagues
(2007), requiring in vivo testing for every
adverse effect within these high-throughput chemical testing programmes would
exceed the capacity of available scientific
facilities and expertise, result in unacceptably high false positive rates, and,
in all likelihood, endanger the success of
these programmes.
Such considerations have generated a
strong interest in alternative testing strategies. This interest was further increased
when challenging timelines for phasing
out animal testing of cosmetics, as well
as marketing bans on cosmetics tested in
vivo after certain chronological deadlines
were imposed within the EU under the
seventh Amending Directive 2003/15/
EC to Cosmetics Directive 76/768/EEC
(Combes et al., 2007; Lilienblum et al.,
2008).
1.1.2

Scientific limitations

The scientific limitations incurred
through modelling humans by animals
within fundamental or clinically-applied
research and toxicity testing are considerable, wide-ranging, and increasingly recognised. These may include differences
between species and genders – with subsequent effects on toxico- and pharmacokinetics (PK: the study of bodily distribution, particularly ADME: absorption,
distribution, metabolism and excretion),
or pharmacodynamics (PD: the study of
mechanisms of action, and drug effects).
They commonly include the use of unrealistic doses and exposure durations; the
loss of biological variability or predictivity, resulting from the use of in-bred
strains, young animals, restriction to single genders, and inadequate group sizes;
the lack of co-morbidities or other human
risk factors; and stress-related physiological or immunological distortions, among
others (Hartung, 2008a,b; Matthews,
2008).
Interspecies variations in P450-dependent monooxygenases are well established
(Guengerich, 2006). These constitute the
major family of xenobiotic metabolising
enzymes – that is, enzymes catalysing the
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oxidation (i.e., the metabolism) of foreign
compounds, such as drugs or toxins. Their
major purpose is the generation of nontoxic blood-soluble metabolites suitable
for renal or other elimination. Interspecies differences in metabolic pathways,
rates and products, may decrease efficacy
or produce toxicity, and are a key cause
of high clinical trial failure rates during
pharmaceutical development (DiMasi et
al., 2003). In fact, only 8% of all drugs
progressing to human trials after demonstration of safety in animal studies gain
FDA licensing approval (Pippin, 2008).
The utility of animal models has been
repeatedly questioned. Of 20 published
systematic reviews examining human
clinical utility located during a recent,
comprehensive search, animal models
demonstrated significant potential to contribute toward the development of clinical interventions in only two cases, one of
which was contentious. Seven additional
reviews failed to demonstrate utility in
reliably predicting human toxicological
outcomes, such as carcinogenicity and
teratogenicity. Results in animal models
were frequently equivocal, or inconsistent
with human outcomes (Knight, 2007).
A European working group comprised
of 18 pharmaceutical companies recently
conducted an evidence-based review of
the value of acute toxicity studies conducted on 74 compounds. Such animalbased studies – which are usually conducted in rodents – have been required
prior to the licensing of pharmaceuticals
intended for human use. This is the only
study type during the process in which lethality is mentioned as an endpoint (Robinson et al., 2008).
However, the acute toxicity data for
these 74 compounds was never used to:
(i) terminate drugs from development,
(ii) support dose selection for subsequent repeat-dose animal studies, or (iii)
set doses, identify target organs, or indicate biomarkers for monitoring in human clinical trials – a minority of which
also occurred prior to animal studies. The
conclusions – which were discussed and
agreed with representatives of regulatory
bodies from the US, Japan and Europe, in
2006 – were that such studies are not necessary prior to first clinical trials in humans, and that sufficient information can

Altex 25, 3/08

be obtained from other studies conducted
at more relevant doses for humans, which
already comprise an integral part of drug
development (Robinson et al., 2008).
1.1.3 Regulatory limitations

Increasing social concern about invasive
animal use within biomedical research
and toxicity testing has driven the evolution of related legislation and regulatory policies within many countries and
regions (for summaries see: http://www.
vetmed.ucdavis.edu/Animal_Alternatives/
policies&regs.html).
In 1986, the Council of Europe, European Treaty Series No. 123 (ETS 123)
on the European Convention for the
Protection of Vertebrate Animals used
for Experimental and Other Scientific
Purposes, was developed. It requires the
consideration of non-animal methods (if
reasonably and practicably available), or
justification of animal use, in which case
minimum numbers are required, with
minimisation of pain, suffering or lasting
harm (Council of Europe, 1986).
Similarly, the 1986 European Directive
86/609/EEC on the Protection of Animals
used for Experimental and Other Scientific Purposes states that: “An experiment
shall not be performed, if another scientifically satisfactory method of obtaining
the result sought, not entailing the use
of an animal, is reasonably and practicably available.” [Article 7.2]. And further, that: “The Commission and Member
States should encourage research into the
development and validation of alternative
techniques which could provide the same
level of information as that obtained in
experiments using animals but which involve fewer animals or which entail less
painful procedures, and shall take such
other steps as they consider appropriate to encourage research in this field.”
[Article 23.1] (Leist et al., 2008b). Such
Directives are legally binding on all EU
member states (Kulpa-Eddy, 2006).
Within the US, the regulations associated with the Animal Welfare Act (AWA,
1966, most recently amended in 1990)
require documented consideration of alternatives, “to any procedure that would
reasonably be expected to cause more
than slight or momentary pain or distress in a human being.” Warm-blooded

vertebrates are protected, with some exceptions – primarily birds, mice and rats
(despite the fact that these rodent species
comprise the overwhelming majority of
laboratory animals). Such consideration
is required whether or not analgesics or
anaesthetics are used, and research must
not unnecessarily duplicate previous
experiments (US Government Printing
Office, 1985; Kulpa-Eddy, 2006; Larson,
2006).
Unfortunately, however, alternatives
must only be considered within the US.
The AWA does not actually require their
use, even when scientifically validated.
Accordingly, a 2007 Petition to the US
Food and Drug Administration for [the]
Mandatory Use of Non-Animal Methods,
filed by a coalition of animal protection
and other organisations, and individual
scientists, seeks changes in Food and
Drug Administration (FDA) regulations
and policies that would require that pharmaceutical companies, device manufacturers and other entities regulated by the
FDA submit data only from scientifically
satisfactory non-animal test methods,
in lieu of corresponding animal-based
methods, whenever such alternatives
are available (MAP Coalition, 2007;
Pippin, 2008). The FDA now requires
only human-based in vitro systems for
the evaluation of drug-drug interaction
potential, with no requirement for animal
studies (Li, 2008a).
1.2 Scientific interest in
alternatives

Increased scientific interest in non-animal alternatives has been reflected by
their ongoing development and formal
validation, and by the establishment of
several international centres and university departments dedicated to this work
(Leist et al., 2008a). In 1981 a Center for
Alternatives to Animal Testing was established at the John Hopkins University
Bloomberg School of Public Health, to
support the creation, development, validation and use of alternatives to animals,
in research, product safety testing and education. In 2004 the British government
established the National Centre for the
Replacement, Reduction and Refinement
of Animals in Research, whose ultimate
aim is the replacement of all animal ex-
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periments. Similar centres exist in Germany, Austria, the Netherlands and Japan. Between 1998 and 2007, 24 distinct
tests or categories of test methods that
could replace, reduce or refine laboratory
animal use were scientifically validated
and registered with the European Centre
for the Validation of Alternative Methods
(ECVAM), an EC organisation. Thirteen
had achieved regulatory acceptance (ECVAM, n.d.).
In 2008 a partnership was announced
between the US National Institutes
of Health (NIH) Chemical Genomics
Center of the National Human Genome
Research Institute, the National Institute of Environmental Health Sciences,
and the EPA (Collins et al., 2008; Hartung and Leist, 2008; Leist et al., 2008b).
The partnership aims to meet the future
toxicity testing needs of the EPA and the
National Toxicology Program (NTP) by
implementing recommendations proposed in the NTP’s Roadmap for the Future (NTP, 2004), and the report of the
National Research Council’s Committee
on Toxicity Testing and Assessment of
Environmental Agents, Toxicity Testing
in the 21st Century: A Vision and a Strategy (NRC, 2007). These reports propose
significantly increased roles for non-animal alternatives, such as high-throughput
robotic molecular and cellular screening
methods. They estimate, for example,
that running 1,408 chemicals through
200 protein and cell-based assays, at
fifteen different concentrations, would
take about two and a half weeks, and cost
around USD 1 million.
1.3 Scientific resistance to
alternatives

However, resistance to the use of alternatives remains considerable, within some
governmental, academic and commercial
sectors. A 2000 survey identified a range
of common areas of non-compliance of
US researchers with the regulations associated with the AWA. The most common
was inadequate consideration of alternatives (at 600-800 research facilities), and
the fourth most common was unnecessary
experimental duplication (at approximately 250 facilities). Other deficiencies
identified included inadequate justification for animal numbers, and alleged
uncertainty of research personnel about
216

signs indicative of pain and/or distress
(USDA-APHIS-AC, 2000).
Similarly, chemical companies submitting HPV test plans to the EPA have
often failed to follow even the minimal
guidance provided by the EPA about alternatives. They have failed to use existing published data individually, or in
conjunction with other data (in a weightof-evidence approach – which aims to review all available, relevant evidence, in
a structured, systematic, independent and
transparent manner (Balls and Combes,
2006)); and have failed to avoid duplicative or otherwise unnecessary animal testing. They have proposed irrelevant tests
(such as acute fish toxicity tests on water-insoluble chemicals), or tests clearly
unnecessary to meet HPV requirements.
Opportunities to use replacement assays,
such as in vitro genotoxicity tests, have
been ignored, and companies have failed
to take advantage of opportunities to combine protocols, sometimes doubling the
number of animals killed. In its responses
to such test plan proposals, the EPA frequently failed to encourage companies
to follow basic animal welfare principles
(Sandusky et al., 2006).
Such attitudes toward biomedical animal use reveal a marked lack of consideration of scientific constraints on the utility
of animal models for human applications,
of social concerns about their use, and
about the unprecedented logistical challenges that reliance on animal models will
inevitably incur, during high-throughput
chemical testing programmes. They also
demonstrate marked and widespread deficiencies in awareness of the potential and
availability of non-animal methods.
Accordingly, for those less familiar with
the alternatives field, this review seeks to
broadly illustrate the potential offered
by non-animal (replacement) methodologies, through examination of selected
examples. As stated by Gruber and Hartung (2004): “Availability and awareness
of adequate in vitro techniques represent
the prerequisites for the use of alternative
methods,” although alternatives are not
limited solely to in vitro methodologies.
This review does not seek to definitively cover any particular sub-discipline
within the sizeable alternatives field, or to
review refinement or reduction strategies,
which have often been well covered else-

where (e.g. Brown et al., 1995; Morton,
1995, 1998; Rowan, 1995; Pellizzer et al.,
2005; Luttun and Verfaillie, 2006).
2 Discussion
2.1 Alternatives to laboratory
animal use

The three Rs (3Rs) of replacement (with
non-animal models), reduction (of animal
numbers), and refinement (to decrease
animal suffering) of laboratory animal
use were first proposed by Russell and
Burch (1959), and have since become
almost universally accepted as fundamental to good laboratory animal practice (e.g. United States Department of
Agriculture (USDA) Policy 12, 2000). As
stated by Russell and Burch, “Refinement
is never enough, and we should always
seek further reduction and if possible replacement. … Replacement is always a
satisfactory answer.” A broad range of
investigative tools exist that may potentially replace sentient animal use within
biomedical research and toxicity testing.
2.2 Sharing and assessment of
existing data

The first step in any toxicological evaluation of a compound, or the commencement of any biomedical research project,
should be a comprehensive and critical
assessment of all existing data, in order
to determine which, if any, remaining
experiments are necessary. To maximise commercial competitiveness, much
existing data remains excluded from the
public domain within pharmaceutical and
chemical company files. However, such
exclusion is contrary to the public interest
when toxicity data regarding the components of new pharmaceutical or consumer
products are not disclosed, when animal
experiments are repeated, and when product development is slowed, as a result.
Accordingly, it is the view of this author
that mandatory disclosure of toxicity data
should be legislated after a short-term
window (which could be waived in special circumstances) designed to retain a
measure of commercial competitiveness
and, thereby, incentive for companies that
generate new data.
A similar view is shared by European
authorities who have made data sharAltex 25, 3/08
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ing mandatory under REACH – both to
reduce vertebrate testing, and potential
costs incurred by industry through duplicative testing. The REACH guidelines
aim to share costs of studies that are already available amongst parties that may
benefit through access to resultant data.
Where additional testing is deemed necessary, the sharing mechanism aims both
to minimise costs and to ensure such
testing is conducted only once (ECHA,
2008).
The Carcinogenicity and Genotoxicity eXperience (CGX) database, freely
offered on the Internet by the scientific education charity, LHASA Limited
(see http://www.lhasalimited.org/index.
php?cat=4&sub_cat=83), provides a
large number of published genotoxicity
results for rodent carcinogens and noncarcinogens, and provides an example of
how such information might be organised
and freely shared.
2.3 Physicochemical evaluation
and computerised modelling

The high costs of drug development have
created a strong incentive for the development of tests able to detect deficiencies,
such as poor absorption, target organ concentration, clearance or efficacy, and toxicity or other adverse effects, early within
the development process. The benefits of
modelling and simulation during drug design and pre-clinical assessment can potentially be realised through integration
of any available data on physicochemical
properties, PK and PD (Balls, 1994; Lavé
et al., 2007; Wishart, 2007).
2.3.1 Biokinetic modelling

Wishart (2007) recently reviewed available tools for modelling and predicting drug ADME. Such tools include:
(1) ADME parameter predictors; (2)
metabolic fate predictors; (3) metabolic
stability predictors; (4) cytochrome P450
(cP450) substrate predictors, and (5)
physiology-based pharmacokinetic (or
biokinetic; PBPK or PBBK) modelling
software.
PK models predict in vivo concentrations of test substances/metabolites and
organ systems affected (Combes et al.,
2007). PBPK models utilise both the
known anatomy and physiology of the
organism (considering properties such
Altex 25, 3/08

as tissue type – e.g. fat vs. muscle, tissue
volume, blood flow rates, known active
transport or biotransformation pathways),
as well as the physicochemical properties
of the compound, to estimate the concentration-time relationship of compounds
within various body compartments and
organ systems (Blaauboer et al., 2006).
Such models can be used to predict optimal doses and dosing schedules, potency,
and, potentially, level of variability and
uncertainty for drug candidates (Wishart,
2007). They may even be used for extrapolation of the biokinetic behaviour
of chemicals between different routes
of exposure or species (Andersen, 1991;
Broadhead and Bottrill, 1997).
Germani and colleagues (2007) provided an example of a PBPK model for
predicting the plasma concentration-time
curves expected after intravenous administration of candidate drugs to rodents.
The predictions were based on a small
number of properties that were either calculated based on the structure of the candidate drug (e.g. octanol:water partition
coefficient, ionisation constant(s)), or obtained from the typical high-throughput
screens implemented in the early drug
discovery phases (fraction unbound in
plasma, and intrinsic hepatic clearance).
Plasma concentration-time curves were
predicted with good accuracy.
2.3.2 Structure-activity
relationships

The relationship between physicochemical structure and biological activity (structure-activity relationship, SAR)
was recognised as early as 1894 by Emil
Fischer (Nobel Laureate, 1902) – who
used the lock-and-key analogy, which
may be used to describe the three-dimensional complementarity of drugs with
target receptors or enzymes (Vedani et
al., 2007a). PD modelling utilises SARs
to predict various biological activities
on the basis of molecular substructures
or other chemical moieties. Quantitative
structure activity relationships (QSARs)
are mathematical descriptions of the relationships between the physicochemical
properties of molecules and their biological activities (Comber et al., 2003), that
may be used to predict characteristics at
the theoretical, compound design stage
(Vedani et al., 2007b).

Due to the large amount of data available for these toxicity endpoints, many in
silico models for the prediction of mutagenicity or carcinogenicity exist. Ashby
and Tennant (1991) demonstrated that the
presence of aromatic amino/nitro-groups,
alkylating agents and certain other chemical groups, increased the likelihood of
rodent carcinogenesis in a survey of 301
chemicals tested by the NTP. Cronin et
al. (2003) described a number of electrophilic molecular substructures common to a range of potential multi-species
toxicants. Matthews and Contrera (1998)
described the evaluation of a QSAR computerised system that demonstrated 97%
sensitivity for rodent carcinogens, and
98% specificity for non-carcinogens. The
sensitivity of a test is its ability to correctly
identify compounds possessing the property of interest (true positives), while the
specificity refers to its ability to correctly
identify compounds lacking the property
of interest (true negatives).
QSARs are often based around models
for particular classes of compounds, such
as amines and aldehydes (Benigni et al.,
2003). Vedani and colleagues (2007b),
for example, described their VirtualToxLab, which utilised an advanced QSAR
modelling system to predict interactions
of drugs and environmental chemicals
with receptors mediating endocrinological disruption or other toxicities. The VirtualToxLab offered nine “virtual test kits”
for the estrogen (α/β), androgen, thyroid
(α/β), glucocorticoid, aryl hydrocarbon
and peroxisome proliferator-activated receptor γ, as well as for the enzyme cP450
3A4. Tests on 798 compounds predicted
binding affinities close to the experimental uncertainty, with only six of 188 test
compounds removed by more than a factor of 10 from the experimental binding
affinity, and the maximal individual deviation not exceeding a factor of 15.
Such in silico systems are ideally suited
for predicting receptor-mediated toxicity caused by drugs and environmental
chemicals. Running VirtualToxLab using
contemporary mid-level computer technology allowed prediction of binding affinities for 150 compounds over a weekend. Vedani and colleagues estimated that
60–70% of the approximately 30,000
chemicals to be re-evaluated within
REACH could be readily processed us217
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ing VirtualToxLab. To improve the applicability and reliability of VirtualToxLab through peer-review, they created a
free internet access protocol available
to selected laboratories, accessible via
admin@biograf.ch.
Such models generally have a strong
mechanistic basis and are often userfriendly and easily understood (Combes
et al., 2007). They are fast, reproducible
and cheap (Vedani et al., 2005). However,
their applicability domains are inevitably
limited (Combes et al., 2007). As long as
some enzyme/receptor systems mediating
toxicity remain unknown, false-negative
results will inevitably occur (Vedani et
al., 2005). QSAR applicability domains
will expand as mechanisms and, particularly, receptors mediating additional toxic
effects, become known. Improved QSAR
models for skin sensitisation, respiratory
irritation and genotoxicity, for example,
are expected soon (Veith, 2006).
2.3.3 Expert systems

Computerised expert systems seek to
mimic the judgment of expert toxicologists by using known rules about factors
affecting toxicity, in combination with
physicochemical or other information
about a specific compound. They make
predictions about toxicity and related biological outcomes, such as metabolic fate.
Gerner and colleagues (2004), for example, described two sets of structural alerts
(fragments of chemical structure) for the
prediction of skin sensitisation hazard
classification, which comprise 15 rules for
chemical structures deemed to be sensitising by direct action, and three rules for
substructures that act indirectly – i.e. requiring chemical or biochemical transformation. Prevalidation against sensitising
chemicals taken from the ̔Allergenliste̓
held by the German Federal Institute for
Risk Assessment yielded some reasonable predictivity rates: positive predictivity, 88%; false-positive rate, 1%; specificity, 99%; negative predictivity, 74%;
false-negative rate, 80%; and sensitivity,
20%. Accordingly, the authors proposed
that these structural alerts should be subjected to formal validation with a view of
incorporating them into regulatory guidelines thereafter.
Expert systems such as MultiCASE,
PASS, DEREK, OASIS/TIMES and Tox218

Scope aim to predict the mutagenicity of
compounds and/or their major metabolites
(Combes et al., 2007). Some systems aim
to predict carcinogenicity or other toxic
endpoints. For example, the EPA has developed an expert system for the prediction of the carcinogenicity of fibres, metals, polymers, and more than 48 classes
of organic chemicals (EPA, 2007), which
is freely available at http://www.epa.gov/
oppt/newchems/tools/oncologic.htm. In
comparison to conventional rodent bioassays, such computerised systems are
rapid and inexpensive.
2.4 Minimally-sentient
organisms

The use of minimally-sentient animals
from lower phylogenetic orders, or early
developmental vertebral stages, as well as
microorganisms, higher plants, and nonliving physical and chemical systems, can
increase compliance with animal use legislation – which frequently regulates only
live vertebrate use.
Cosson (2007), for example, proposed
the development of protozoal – rather
than rodent – assays for bacterial infection, based on the fact that pathogenic
bacteria such as Pseudomonas aeruginosa often use the same mechanisms to
defend themselves against phagocytosis
by unicellular amoebae, and to infect
mammalian cells.
The UK Animals (Scientific Procedures) Act (1986; Anon, 1986), for example, allows unregulated use prior to
half-way through gestation (in the case
of mammals), or incubation (birds and
reptiles), or the stage when independent
feeding occurs (amphibians and fish). For
example, early chicken embryos may be
used in reproductive toxicity tests without
restriction, and parasites may be similarly
cultivated in chicken eggs, for use in parasitological studies (Balls, 1994; Eckert,
1997).
Such strategies may also minimise ethical concerns – although not necessarily to
the extent apparent on first examination.
For example, there is no clear demarcation between the sentience (and consequent ability to suffer in experiments) of
some lower vertebrates, such as certain
fish species, and some higher invertebrates, such as certain cephalopod molluscs. Similarly, the stage of development

at which animals pass from a legislatively
unprotected to a protected state (at least,
within the UK), is rarely based on strong
scientific justification. Such examples
demonstrate the necessity of making decisions appropriate to each case based
on both the best available scientific evidence, and also a precautionary principle,
mandating that where reasonable doubt
exists about sentience, animals should be
accorded the benefit of that doubt (Balls,
1994).
2.5 Tissue cultures

Tissue cultures are in vitro cultivations of
cells, tissues, organs or embryos. Primary
cell cultures are isolated directly from
animal tissues, often using proteolytic
enzymes. Their major advantages include
tissue-specific functions and retention of
capacity for biotransformation. However,
cellular isolation can result in damage to
cell membrane integrity, with loss of, or
damage to, membrane receptors and cellular products. Fortunately, during the
interval necessary to establish monolayer
cultures from cell suspensions, such cell
damage is often repaired (Broadhead and
Bottrill, 1997).
Due to the adverse changes that occur
within primary cultures maintained for
prolonged periods, it may be necessary
to isolate new cells for each experiment.
Cell lines eliminate this need. However,
extended periods of culture over many
years can result in decreased metabolic
capacity and altered cellular function.
Widely used animal-derived cell lines,
such as Chinese hamster ovary cells and
mouse lymphoma L5178Y cells, suffer
from variation in phenotype and behaviour between laboratories, even with respect to chromosome numbers (Broadhead and Bottrill, 1997).
Immortalised cell lines are capable of
extended, and often indefinite, growth
in vitro. They are generated by introducing viral oncogenes such as SV40 large
T, polyoma virus large T and adenovirus
EIA, into primary cells, using calcium
phosphate or electroporation treatment.
Examples of cells that have been immortalised include rabbit kidney cells, mouse
macrophages, rat hepatocytes, and human
lymphocytes and osteoblasts (Broadhead
and Bottrill, 1997). Immortalisation of
cell lines, however, may significantly alAltex 25, 3/08
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ter their characteristics and function (Luttun and Verfaillie, 2006).
Stem cell lines can be established from
mammalian blastocysts (embryonic stem
cells (ESCs); Huggins, 2003), or from
adult progenitor cells (multipotent adult
progenitor cells; Luttun and Verfaillie,
2006). SCs can be maintained in an undifferentiated state in the presence of feeder
layers and/or purified leukaemia inhibitory factor (LIF) (Brown et al., 1995).
Upon removal of the LIF, SCs differentiate into a variety of cell types (Brown et
al., 1995), making them ̔pluripotent̓ in
the case of ESCs, or ̔multipotent̓ when
isolated from adult organs.
The differentiation potential of adult
stem cells was long believed to be limited,
although recent evidence has challenged
this concept. However, SCs derived from
human embryos (hESCs) raise considerable ethical and sociological concerns.
The broader the differentiation potential,
the more applications can be considered
for each stem cell type. As with immortalised cell lines, the self-renewal capacity
and potentially unlimited availability also
make SCs particularly attractive as a research tool (Luttun and Verfaillie, 2006).
Much of the considerable interest in
SC research centres on their potential to
replace lost tissue or functional cells, for
example, in degenerative diseases (Luttun and Verfaillie, 2006). In a related
application, SC research has helped to
elucidate some of the proliferation and
differentiation mechanisms involved in
haematopoiesis (blood cell production) –
and, particularly, several haematopoietic
cytokines (controlling proteins), which
are now used in the treatment of cancer
patients undergoing chemotherapy and
radiation therapy – which frequently suppresses haematopoiesis (Luttun and Verfaillie, 2006).
Organ cultures are three-dimensional
and retain some or all of the histological
features of the in vivo equivalent. They
may be derived from differentiated SCs.
Complex organotypic culture systems,
with cofactors and metabolic supplements
added, may be used to increase longevity and maintain cellular differentiation
(Broadhead and Bottrill, 1997).
One important potential application is
the creation of artificial liver constructs
for biotransformation studies and drug
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toxicity testing (Luttun and Verfaillie,
2006). One of the functionally important
structural elements of the liver is the sinusoid, which is comprised of a fenestrated
vascular structure decorated with hepatocytes. In the adult liver, sinusoids are
radially aligned, running from the lobule
periphery to the central vein. Odde and
Renn (2000) recently developed “laserguided direct writing” (LGDW), enabling
the positioning of multiple cell types onto
biological matrices with micrometer precision. Cell viability was not significantly
impaired (Nahmias et al., 2004). These
results suggest that LGDW might be used
to create a vascular backbone for ex vivo
liver morphogenesis. LGDW could also
be used to distribute beads coated with
different growth factors onto stem cells,
in order to induce their differentiation in
a specific spatial pattern (Luttun and Verfaillie, 2006).
Cultures of tissue explants, such as liver
slices, may also be used. Their advantages include speed and ease of preparation,
the presence of multiple, differentiated
cell types, and the maintenance of cellcell and cell-matrix interactions. However, maintenance of viability is difficult,
and their use was originally described by
Russell and Burch (1959) as relative replacement, because animals are killed to
provide cells, tissues and/or organs, and
distinct from the ideal of absolute replacement, in which sentient non-human
animals are not used at all (Broadhead
and Bottrill, 1997).
Tissue cultures can play a valuable role
in a variety of interesting toxicological
investigations. For example, a number
of complementary DNA segments (from
which the non-coding intron sequences of
the original DNA have been excised; cDNA) coding for human cP450 enzymes
have been cloned, incorporated into eukaryotic expression vectors, and introduced into cell lines, which are then used
to study the metabolic capacity of individual cP450 enzymes. Such information
may then facilitate identification of compounds that become toxic after biotransformation by these enzymes (Broadhead
and Bottrill, 1997).
Similarly, cell lines generated to carry
recombinant shuttle vectors can be used
to study eukaryotic mutation, because
the vectors can be exposed to mutagenic

agents in mammalian cells and then transferred to bacteria for rapid analysis of the
mutations. Such cell lines can be used for
short-term in vitro mutagenesis studies,
DNA repair studies, and for studies of the
effects of oncogenes, mutator genes and
tumour suppressor genes, on mutant frequencies (Broadhead and Bottrill, 1997).
2.6 In vitro assays

In vitro assays utilising bacterial, yeast,
protozoan, mammalian or human cell cultures exist for a wide range of toxic and
other endpoints, including skin corrosion/
irritation, phototoxicity, eye corrosion/
irritation, skin absorption, skin sensitisation, carcinogenicity and systemic toxicity (Huggins, 2003; Murthy, 2007). In
vitro assays are not without their limitations (Hartung, 2007). Nevertheless, some
have been scientifically validated (demonstrated to be reliable and relevant for
the intended purpose; Balls et al., 1990),
whilst many others remain under rapid
development (Huggins, 2003). A definitive review of the sizeable and speedily
evolving field of in vitro assays is well beyond the scope of this review; however,
examination of selected assays serves to
illustrate their broad potential.
2.6.1 Perfused cultures

Tissue cultures may be static or perfused
with culture media via pumps. When exposed to toxins, perfusion cultures may
allow continuous real-time monitoring of
cytotoxicity, through detection and measurement of biomarkers in the perfusion
outflow. This can yield important information about onset time, duration and
scale of toxicity, which are more difficult
to obtain from static cultures or in vivo
assays, unless highly specific organic biomarkers indicative of tissue damage are
detectable in bodily fluids, such as blood
or urine. However, the increased complexity of perfused cultures may limit
their use to low-throughput analysis (Jennings et al., 2004).
2.6.2 Carcinogenicity assays

In vitro genotoxicity assays are based on
the detection of mutagenicity in bacteria
or chromosomal damage in mammalian cells. Bacterial mutagenicity assays
utilise tester/indicator strains which are
hypermutable due to defective cell enve219
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lopes (which enhance the uptake of test
chemicals), or deficiencies in DNA repair
mechanisms. Different strains may be
used to detect chemicals that induce mutagenesis through different mechanisms
(Combes et al., 2007).
Mammalian genotoxicity assays often
use primary cell isolates, usually of human origin (e.g. lymphocytes), or permanent cell lines, often derived from
Chinese hamsters (e.g. ovary or lung)
(Mitchell and Combes, 1997). DNA lesions induced following test chemical exposure may include structural aberrations
(such as chromosome gaps and breaks
induced by clastogens), micronuclei (intracellular supernumary chromatin), or
sister chromatid exchanges, as well as
numerical abnormalities (e.g. polyploidy
and hypodiploidy/hyperdiploidy), indicative of aneuploidy (the state of having a
chromosome number that is not an exact
multiple of the haploid number) (Parry
and Parry, 1995; ECETOC, 1997). Such
chromosomal abnormalities are detected
following cell replication, using a variety
of staining methods or other visual aids
(ECETOC, 1997).
Such genotoxicity assays may play an
important role in carcinogenicity testing. Brusick (1977), for example, found
a correlation of approximately 90% between in vitro microbial mutagenesis and
mammalian carcinogenic endpoints for a
large array of chemicals. Tennant and colleagues (1990) successfully predicted the
outcomes of 86% of 44 chemicals undergoing carcinogenicity testing by the NTP,
by using the Salmonella mutagenicity and
sub-acute (90-day) rodent toxicity tests, in
combination with chemical structural information. The Ames Salmonella typhimurium reverse mutation and chromosomal
aberration (CA) genotoxicity assays have
been accepted by regulatory agencies for
many years (Dearfield et al., 1991).
Cell transformation assays (CTAs) detect morphological changes that provide
the earliest phenotypically identifiable
signs of carcinogenicity. In fact, these
assays provide the main non-animal
methods for modelling carcinogenicity,
and were comprehensively reviewed by
Combes and colleagues (1999, 2007).
CTAs may be used to detect both genotoxic and non-genotoxic carcinogens (GCs
and NGCs).
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CTAs have been devised using rodent
cell lines (e.g. Balb/c 3T3 cells; Tsuchiya
and Umeda, 1995, Tsuchiya et al., 1999),
and immortalised fibroblast cell lines of
rodent or human origin (e.g. C3H10T1/2
cells; Reznikoff et al., 1973; Landolph,
1985). The Syrian hamster embryo (SHE)
cell transformation assay has been described as the most predictive short-term
assay for rodent carcinogens (Zhang et
al., 2004). Pienta and colleagues (1977)
showed a 91% correlation between the
morphological transformation of SHE
cells – despite their prior cryopreservation – and the reported carcinogenic
activity of numerous carcinogenic and
non-carcinogenic chemicals. The particular advantage of the SHE assay in comparison to many other in vitro assays is its
high sensitivity for NGCs, as well as GCs
(Amacher and Zelljadt, 1983; Mauthe et
al., 2001).
Whilst GCs often exert their effects
across a range of species, sexes and target organs, the detection of NGCs may be
particularly challenging, because of the
wide diversity of their potential modes of
action, which are often species-, sex- and
tissue-specific. Some exert their effects
after binding to specific cellular receptors, whilst others involve epigenetic
changes coupled with cellular proliferation. Some mechanistically-based assays
are being developed and used specifically
for the detection of such NGCs. Examples
include: assays designed to detect ligand
binding to nuclear and cell membrane
receptors, e.g. Ah receptor binding; in
vitro reporter gene assays to detect binding resulting in up-regulation of receptors
or transcriptional activation; in vitro cell
proliferation assays, e.g. the serum-free
liver mitogen test; the in vitro gap junction intercellular communication (GJIC)
assay, designed to detect the inhibition of
GJIC believed to result from exposure to
some NGCs; and the in vitro detection of
angiogenesis, to assess the ability of the
test substance to elicit the later stages of
tumourigenesis (Combes, 2000; Combes
et al., 2007).
2.6.3 Test batteries

Batteries of in vitro assays may be used
to increase the spectrum of toxins detected (applicability domain). Kirkland
and colleagues (2005) examined the

ability of a battery of three of the most
commonly used in vitro genotoxicity assays: the Ames Salmonella typhimurium,
the mouse lymphoma assay, and the in
vitro micronucleus or CA tests, to correctly predict the rodent carcinogenicity
of 700 known chemicals. While the sensitivity of the battery was high (93% of
chemicals with reliable genotoxicity data
yielded positive results in at least one
test), the specificity was variable. The
low specificity of the mammalian cell
assays declined further when combined
as a battery. However, by adopting relative predictivity (RP) ratios of true:false
results, it was established that positive
results in all three tests indicated that rodent carcinogenicity was more than three
times likelier than non-carcinogenity, and
also that negative results in all three tests
indicated that rodent non-carcinogenicity
was more than twice as likely as carcinogenicity. Accordingly, the authors recommended the use of RP ratios to assess the
likelihood of carcinogenicity or non-carcinogenicity, for chemicals with batteries
of positive or negative results.
2.6.4 GreenScreen genotoxicity
assays

Lichtenberg-Frate and colleagues (2003)
demonstrated the genotoxic and cytotoxic sensitivities of a genetically modified yeast (Saccharomyces cerevisiae)
assay that used a yeast-optimised version of green fluorescent protein fused
to the RAD54 yeast promoter, which is
activated upon DNA damage. The result
was green fluorescence in the presence of
several genotoxic test compounds. This
elegant assay was thereafter known as a
GreenScreen.
A similar assay appeared to detect a
number of genotoxins and non-genotoxins with a very high level of accuracy, in
a study of some 75 chemicals (Hastwell
et al., 2006).
Akyüz and Wiesmüller (2003) also
described a GreenScreen assay for the
detection of genotoxicity, but in this case
living human cell cultures were studied.
The assay detected the genotoxic effects
of ionising radiation, of a compound that
tested positive in a traditional Ames bacterial mutagenicity assay, and also, of two
compounds that were poorly mutagenic
in the Ames assay.
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As Cahill and colleagues (2004) observed, the spectrum of compounds detected by the GreenScreen is somewhat
different to that detected by bacterial genotoxicity assays, and hence this assay,
when combined with a high-throughput
bacterial screen and an in silico SAR
screen, might provide an effective battery
of genotoxicity screening tests for regulatory purposes.
Additional advantages include the possibility of assessing the impact of human
metabolites, for example, by the addition
of liver extracts, or by using transgenic
cell lines with human metabolising enzymes. The potential for automated performance and flow cytometric analysis
also make the human-based assay described by Akyüz and Wiesmüller amenable to high-throughput.
2.6.5 Human hepatocyte assays

Human hepatocyte assays play a key role
in pharmaceutical development. The liver
usually receives the highest bolus concentration of an ingested drug, delivered
from the intestines via the portal circulation. Furthermore, hepatocytes produce
P450-dependent monooxygenases, and
hence, are the major cells responsible
for drug metabolism, and the first cells to
be affected by any reactive or toxic metabolites produced. Accordingly, human
hepatocyte cultures are the in vitro system
of choice when studying human drug-induced processes (Ullrich et al., 2007; Li,
2008a). They are now routinely used for
metabolic profiling (identification of metabolites formed from the parent drug),
and the assessment of drug-drug interaction potential and toxicity, in both academic and industrial laboratories. Standardised and validated human hepatocyte
culture systems now exist (e.g. Ullrich
et al., 2007). The development of cryopreservation using protocols and reagents
designed to protect membranes from
damage associated with cryopreservation
and subsequent thawing, and the development of protocols and media allowing
cultivation of differentiated, functional
human hepatocytes, have all facilitated
their widespread use (Ullrich et al., 2007;
Li, 2005, 2008a).
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2.6.6 Assesment of
metabolite activity and organorgan interaction

The inability of most cell cultures to
mimic organ-organ interactions occurring
in vivo represents an important limitation
of isolated organ cultures. The importance of considering multiple organ interactions is illustrated by the potential generation of toxic metabolites by the liver,
which may exert effects in distal organs
(Li, 2008b). Although such reactive metabolites are believed to constitute a significant proportion of all toxins, for most
compounds the degree of toxicity resulting from metabolic activation is unknown
(Langsch and Nau, 2006).
Hence, models such as the Integrated
Discrete Multiple Organ Co-culture
(IdMOC) system developed by Li and
colleagues (2008b) are particularly significant. Developed for the evaluation of
xenobiotic toxicity, the IdMOC system
utilises a wells-in-a-well structure. Cells
from different organs are co-cultured in
discrete inner wells, but interconnected
by an overlying medium integrated into
the outer well. The system models multiorgan human or animal in vivo systems,
in which organs are physically separated
yet interconnected via the systemic circulation. Physical separation of different
cell types facilitates evaluation of organspecific effects, which is extremely difficult when using mixed-cell type cocultures.
Potential applications of the IdMOC
system include the evaluation of multiple-organ metabolism, as well as organspecific drug distribution and toxicity.
Maximal human relevance is achieved
through the use of human xenobiotic
metabolising cells, such as hepatocytes,
and human target organ cultures. A particularly interesting application is the
co-culturing of cancer cells and cells representing major organs, for the selection
of anticancer agents with minimal organ
toxicity (Li, 2008b).
Given that pathways of metabolic activation are frequently uncertain – particularly during high-throughput screening,
such metabolic activation systems should
ideally include all possible relevant hepatic or other enzymes (Langsch and
Nau, 2006). Such preparations may also
be used to identify metabolic pathways

and enzyme systems involved in biotransformation, and active metabolites
produced.
2.6.7 Quality control of
biologicals

Regulatory safety and potency testing
for biological materials, such as vaccine
batches, has traditionally relied on animal
models. Indeed, the quality assurance
and production of medicines accounts for
around 15% of all regulated EU scientific animal use (Leist et al., 2008a). Such
tests are responsible for a high proportion of experiments resulting in severe,
unrelieved pain and suffering (Stephens
et al., 2002). However, the consistency
approach has facilitated reductions in
such animal use within the field of vaccine testing. Each vaccine batch is recognised as one of a series produced from
the same starting material (seed lot),
which shares many common characteristics with other batches, rather than as a
unique product. This allows for a quality
control strategy focusing on production
consistency, achieved through compliance with Good Manufacturing Practice
and Quality Assurance principles, and
assessment at various stages during the
production process using non-animal
test models, such as physicochemical
methods and in vitro assays. Examples
of recent achievements in the quality
control of toxoid vaccines include the
replacement of challenge procedures by
serological methods, and reductions in
animal numbers achieved by changing
from multi- to single-dose testing (Hendriksen, 2006).
Pyrogens (fever-inducing contaminants) can be a major health hazard in
parenteral drugs, when cytokines such as
interleukin-1β, interleukin-6 or tumour
necrosis factor-α are produced. These
cytokines may produce acute adverse reactions that can range from induction of
fever to life-threatening pyrogenic shock
with multi-organ failure (as occurred in
the case of TGN1412 – see following),
depending on the concentration of the
stimulus and its intrinsic activity (Montag
et al., 2007). Hence, pyrogen testing may
be required prior to batch release (e.g.
the European Pharmacopoeia made such
testing of small volume parenterals obligatory in 2004). This was traditionally
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achieved by the in vivo rabbit pyrogen
test (since 1942) or the limulus (horseshoe crab) amoebocyte lysate test (LAL,
since 1976).
However, six variants of human immune cell-based assays have been validated in a collaborative international study.
Such human in vitro assays can achieve
sensitivities and specificities of greater
than 90% for human pyrogens, and – in
contrast to the LAL – may detect nonendotoxic pyrogens derived from Grampositive bacteria or fungi (Schindler et al.,
2006a,b). Sensitivity and consistency may
also exceed that of rabbit assays (Schindler et al., 2007). They may also provide
insights into mechanisms of pyrogenicity
and acute pro-inflammatory reactions in
patients (Montag et al., 2007).
2.6.8 Drug hypersensitivity
prediction

Drug hypersensitivity reactions are
known to be mediated by covalent binding of drug haptens (partial antigens) to
proteins, which are processed to peptides
and presented on MHC-structures (major
histocompatability complexes, comprised
partly of human leukocyte antigen). These
hapten-peptide complexes are recognised
by T cells with receptors (TCRs) that fit
the antigen in question (Pichler, 2007).
However, using blood mononuclear
cells, Pichler (2007) showed that direct
non-covalent binding of drugs to TCRs
is also possible, and may also stimulate
T cells into dividing and triggering inflammatory responses through cytokine
secretion, resulting in cell death (p-i concept– direct pharmacological interaction
of drugs with immune receptors).
Such immune-mediated inflammatory responses may cause mild symptoms, such as maculopapular exanthema,
through to severe reactions, such as Stevens-Johnson Syndrome, toxic epidermal
necrolysis, hepatitis, pancreatitis, fever,
vasculitis, eosinophilia, and even death
(Pichler, 2007).
For testing the safety of systematically
(orally or parentally) applied drugs that
act via this p-i mechanism, human-based
in vitro assays are necessary, because
such immunological reactions are highly species-specific. Small alterations of
TCR morphology may dramatically alter
T cell reactivity. Furthermore, reactivity
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varies even between human individuals,
both in vivo and in vitro, for reasons that
are hypothesised to include variations in
TCR repertoires, immune regulation and
genetic background. Pichler speculated
that a greater understanding of these factors could lead to novel human-based in
vitro assays for drug hypersensitivity.
2.6.9 Bone-seeking
pharmaceuticals

Treatment and monitoring of osseous
tumours requires bone-seeking pharmaceuticals, such as radioactively labelled
polyphosphonates (MDP, DPD, EDTMP,
etc.). Despite their use for over 30 years,
however, uncertainty about the binding
interaction between bone-seeking pharmaceuticals and target bone impedes rational drug design of novel bone seekers,
such as analysis of SARs. Accordingly,
biodistribution and efficacy studies in
laboratory animals have traditionally
been utilised early in preclinical evaluation (Mitterhauser and Toegel, 2008).
Mitterhauser and Toegel, however, described an in vitro assay based on simple
binding to hydroxyapatite (Ca5(PO4)3OH
– a mineral phosphate of calcium that is
the principal structural element of vertebrate bone). In vitro binding characteristics correlated well with those obtained
in vivo using mice, and ex vivo using human donor bone. Accordingly, this assay
provides a viable alternative to animal
models for the comparative evaluation of
novel bone seekers.
2.6.10 Developmental toxicity
assessment using embryonic
stem cells

Organisation for Economic Cooperation
and Development (OECD) Test Guidelines for the assessment of developmental toxicities such as embryotoxicity and
teratogenicity are costly and time consuming. Two- or multigeneration studies
may consume up to 3,200 animals per
substance (OECD Test Guideline 414:
Prenatal Developmental Toxicity Study),
and it is expected that developmental
toxicity testing will consume the highest
animal numbers within REACH (Pellizzer et al., 2005).
The use and further development of
appropriate in vitro systems is therefore
a high priority. These may include cell

cultures (e.g. embryonic stem cell tests
(ESTs)), organ cultures (e.g. micromass
assays), and embryo cultures (e.g. whole
embryo cultures) (Huggins, 2003; Pellizzer et al., 2005). Brown (1987), and
Brown and colleagues (1995), provided
extensive overviews of existing in vitro
systems. The ability of ESCs to differentiate into a wide range of potentially
vulnerable target tissues maximises their
utility. They may be used to test for embryo toxicity in vitro, and to screen for
teratogenicity and growth retardation
(Luttun and Verfaillie, 2006). hESCs are
preferable, as resultant assays are relatively simple and reproducible, avoid interspecies differences, and may facilitate
study of human development.
Several approaches are possible using ESCs. Traditionally, toxicity has
been assessed by morphological analysis of toxic inhibition of beating cardiomyocytes in embryoid body outgrowths
derived from murine ESCs (Luttun and
Verfaillie, 2006), although the objectivity
of this assay has been criticised (Buesen
et al., 2004). An immunological assay
was described by Seiler and colleagues
(2002 and 2004), which utilised intracellular staining and flow cytometry to detect changes in sarcomeric myosin heavy
chain and alpha-actinin during cardiac
differentiation of ESCs. Cultivation of
transgenic ESCs with green fluorescence
protein, driven by a specific tissue gene
promoter, may allows visual detection of
teratogenicity (Metzger et al., 1996; Kolossov et al., 1998; Bremer et al., 2001;
Paparella et al., 2002). Array technologies (see following) now allow detection
of changes in the expression of thousands of genes simultaneously (Lockhart
and Winzeler, 2000), following chemical
exposure. Analysis of gene expression
profiles at different stages of cardiac and
skeletal ESC differentiation has been
used to identify developmental stages of
chemical vulnerability (Pellizzer et al.,
2004a,b).
An international ECVAM study validated the EST using a set of 20 reference compounds characterised by highquality in vivo embryotoxicity data from
laboratory animals and humans. The
EST predicted the embryotoxicity of
the 20 compounds with 78% accuracy,
and 100% predictivity was obtained for
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strong embryotoxins (Genschow et al.,
2002, 2004). Similarly, Whitlow and colleagues (2007) recently conducted ESTs
on six chemicals with toxicity characteristics established from literature and this
ECVAM study, and on 10 Roche internal
pharmaceutical substances already tested
in vivo. Their EST model correctly classified 81% of substances.
Clearly, ESCs offer several avenues
for the identification and investigation
of teratogenicity, in a wide range of differentiated tissues, although ESTs only
detect embryotoxicity occurring early
in embryogenesis. However, detection
of compounds that show such toxicity
is a high priority (Buesen et al., 2004).
In recognition of this, and of their potential during embryotoxicity testing, investigation of hESCs is included within
an important integrated project entitled
ReProTect, which is part of the 2002 EU
6th Research Framework Programme.
The ReProTect collaboration includes 35
academic, governmental and other institutions, and was allocated € 9.1 million
over 5 years. Its principal aim is to create
new in vitro models, and combine these
with existing models within a test strategy aimed at providing information on
chemical hazards to the mammalian reproductive cycle (Pellizzer et al., 2005).
Considerable standardisation and harmonisation of hESC assays remains necessary, however, along with enlargement
of the reference database and consolidation of the details of the existing prediction model, to ensure their regulatory acceptance. The introduction of a metabolic
system as an adjunct to the validated EST
protocol – which is only applicable for
compounds that do not need metabolic activation – will also be necessary (Buesen
et al., 2004).
Varying international approaches
to embryo protection and other ethical issues raised by hESC research also
present significant obstacles (Pellizzer et
al., 2005). Among other restrictions within the relevant 2003 EC guidelines, for
example, is the statement that, “Research
will be funded only when there is no adequate alternative available. In particular,
it must be demonstrated that one cannot
use existing embryonic or adult stem cell
lines” (EC, 2003).
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2.6.11 Brain tissue cultures

Bacterial meningitis has an in-hospital
mortality of approximately 25%, and up
to 50% of survivors suffer neurological
sequelae secondary to brain damage.
Evidence suggests that lesions result primarily from host immune responses. To
date, the pathogenesis of brain infections,
and the efficacy of potential therapeutic
approaches supporting brain repair, have
been largely investigated in animal models, many of which experience suffering
graded as intermediate to severe. In vivo
models have been considered necessary,
because of the complexity of the pathogenesis of meningitis, which involves
interactions between the host’s inflammatory system, susceptible brain cells
and the bacterial pathogen itself (Leib,
2007).
Leib (2007), however, described the
development of an in vitro model aimed
at reproducing important pathophysiological processes of damage and tissue
regeneration, in infectious brain diseases.
Objectives include differentiating neuronal stem cells into defined developmental
stages susceptible to injury, and subsequently challenging them with infectious
pathogens, and/or inflammatory mediators; and also, to evaluate the integrative
and therapeutic potential of neuronal precursors or stem cells, as transplants into
brain tissue. Leib and colleagues have developed an organotypic cell culture system capable of facilitating the culturing
of hippocampal or cortical brain tissue,
whilst maintaining key elements of natural architecture, and natural distribution
of cell types. Brain injury secondary to
bacterial meningitis prominently affects
the cortex and hippocampus.
2.6.12 Genetic engineering

Incorporation of green fluorescent protein
into cells to provide visual confirmation
of genetic damage has been previously
described. Another particularly important
application of genetic engineering is the
incorporation of endogenous xenobiotic
metabolising enzymatic ability within
established cell lines. This can confer the
ability to screen for toxicity and provide
information about molecular mechanisms
of metabolism.
Xenobiotic metabolising enzymes
have now been expressed in bacteria,

yeast, insect and mammalian cells. Over
20 cell lines, mostly derived from human and hamster tissues, have been genetically engineered for the expression of
xenobiotic metabolising enzymes, within
the last decade. Much of this development has relied on recombinant DNA
techniques (Weibel et al., 1997). cDNA
encoding for nearly every major human
P450 isoform has been isolated and sequenced (Crespi, 1995).
Recent research has focused on the isolation of the activity of single enzymes
within a metabolic profile, followed by
study of the activities of multiple enzymes acting in sequence, as occurs in
vivo. Despite considerable progress in
this field, concerns remain about in vivo
applicability, and much validatory work
remains necessary (Huggins, 2003).
2.7 Toxicogenomics

Toxicogenomics is the application of genomics (the study of genomes), to toxicology. Related fields include transcriptomics, proteomics and metabolomics.
Toxicogenomics seeks to link induced
gene expression changes with classes of
toxic compounds (Farr and Dunn, 1999;
Aardema and MacGregor, 2002). For
example, Ellinger-Ziegelbauer and colleagues (2008) identified gene expression
profiles characteristic of GCs and NGCs
based on liver samples from rats treated
for up to 14 days. Based on these results,
they were able to predict the carcinogenicity profiles of an independent set
of validation compounds with up to 88%
accuracy.
cDNA microarrays (gene chips) contain hundreds or thousands of microscopic spots of cDNA transcripts of
mRNA templates. They offer the ability
to examine many genes simultaneously,
and to characterise phenotypic changes in
whole cells or organs. This may considerably speed up the generation of results,
in comparison to less modern methods,
such as the analysis of mutation frequency by phenotypic selection, analysis of
transcription (mRNA) by Northern blotting, or analysis of translation (proteins)
by Western blotting. Furthermore, with
durations of days rather than years, and
with the ability to detect toxic changes
well prior to traditional, more invasive
endpoints, cDNA microarrays may facili223
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tate considerable refinement of laboratory
animal use (Knight et al., 2006a).
Particularly exciting is the ability
of cDNA microarrays to detect NGCs
(Goodman, 2001). After exposing rat
hepatocytes to several rodent GCs and
NGCs, as well as to two non-carcinogenic hepatotoxicants, during five day,
repeat-dose in vivo studies, Kramer and
colleagues (2004) hybridised fluorescently-labelled probes generated from liver
mRNA against rat cDNA microarrays.
Correlation of the resulting data with the
estimated carcinogenic potential of each
compound and the dose level identified
several candidate molecular markers of
rodent non-genotoxic carcinogenicity,
including transforming growth factor-βstimulated clone 22 and NAD(P)H cP450
oxidoreductase.
However, microarray technology remains very new, and a number of existing limitations would benefit from further
research and development (Knight et al.,
2006a). It is expected that many of the
genes affected by toxicant action will be
identified within the next twenty years,
leading to progressively greater utility of
gene chips as replacements for animal use
within toxicity testing (Huggins, 2003).
2.8 Other human studies
2.8.1 Clinical trials

Clinical studies in human volunteers are
an essential component of drug development. They seek to identify differences
between the effects of pharmaceuticals
in preclinical studies, and humans, and to
evaluate their human safety and efficacy.
In 2006, however, during a UK Phase 1
(first-in-humans) trial on the anti-inflammatory monoclonal antibody TGN1412,
all six volunteers rapidly developed cytokine release syndrome after dosing,
culminating in multiple organ failure, requiring intensive care. One volunteer suffered permanent damage. These severe
adverse reactions occurred despite thorough preclinical trials, which had included computer modelling, and tests on human cells, mice, rats, New Zealand White
rabbits, marmosets, rhesus macaques and
cynomolgus monkeys, and despite subsequent authorisation by the Medicines and
Healthcare Products Regulatory Agency,
and the relevant institutional Medical
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Ethics Committee. They occurred despite
correct drug manufacturing processes and
administration in accordance with approved protocols (Northwick Park Hospital, 2006; MHRA, 2006; Bhogal and
Combes, 2006).
Such cases highlight the lack of certainty of existing preclinical studies when
predicting human risks, and the necessity
of compliance with measures designed
to minimise those risks. Such measures
were discussed in detail by Bhogal and
Combes (2006), and at a recent NIH meeting (Kramer et al., 2006). They include:
1. Releasing the outcomes of pre-clinical
and clinical studies into the public domain, either once the drug is marketed
or when it has been deemed to fail.
Such data may guide further research
and development, and may influence
the design of future clinical trials. Such
safety and efficacy-based considerations must be correctly acknowledged
as superseding concerns about commercial confidentiality.
2. Greater effort should be invested into
the development and use of preclinical test methods more predictive for
human outcomes, particularly the use
of human cells and tissues in culture,
and especially in areas presently poorly
modelled, such as the immune system
(Silliman and Wang, 2006). Data from
such tests should be considered at least
as important as traditional animal test
data.
3. The first administration to humans
should utilise microdoses (Phase 0
studies). The role of microdoses in
early drug development was recently
reviewed by the FDA (CDER, 2006).
Microdose studies generally seek to
provide information on human pharmacokinetics and bioavailability (Combes
et al., 2003), rather than pharmacological effects. They use doses less than
1/100th of pharmacologically active
doses, as estimated from preclinical
studies. However, they may not exhibit
threshold or other dose-dependent effects.
4. Increased research should be conducted with the goal of identifying biomarkers of toxicity, such as the presence
of metabolite activating and detoxifying enzymes (Besaratinia et al., 2002),
cellular markers of exposure, the pres-

ence of mutagens in body fluids, and
chromosomal alterations (Cone and
Rosenberg, 1990). Volunteers should
be carefully monitored for the expression of such biomarkers following
microdosing, with assessed biological
parameters expanded to incorporate
possible macroscopic effects, as doses
are increased.
5. Dosing should be staggered, rather
than concurrent, perhaps based on expected in vivo half-lives. In the case
of TGN1412, adverse clinical signs
were evident within two hours of dosing; hence staggering doses by as little
as one hour would have significantly
reduced the number of volunteers affected.
6.	The limited predictivity for broader
populations of human clinical trials may
result from their focus on small groups
of healthy young men, or from insufficient study durations. Particularly in
Phases I-II, small cohorts of young men
(20-300) are typically used to minimise
experimental variability, and to eliminate possible endocrinological disruption or other risks to women of reproductive age. Although 1,000-3,000
volunteers may be used in Phase III
trials – the final phase before marketing
(NIH, 2006) – it is nevertheless clear
that cohort numbers, study durations or
other aspects of protocol design, conduct or interpretation are inadequate
to detect the adverse side effects of the
large number of pharmaceuticals that
harm patients after marketing. Longer
studies of more broadly representative
human populations would be more predictive.
7. When drugs are specifically targeted to
modulate systemic processes, such as
immune system activity, serious consideration should be given to using appropriate patients, rather than healthy
volunteers, as soon as physiologically
active doses are reached. Immunocompromised patients, for example, might
not display the adverse reactions elicited in healthy, immunocompetent volunteers.
Such strategies would probably increase the already substantial time and
cost of pharmaceutical development.
However, with adverse reactions to pharmaceuticals comprising the 4-6th leading
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cause of death in US hospitals (based on
a 95% confidence interval; Lazarou and
Pomeranz, 1998), it is clearly necessary
to question the safety for human patients
of the traditional drug testing paradigm.
2.8.2 Epidemiological,
sociological and psychological
research

Despite our extensive tradition of animal
testing, little certainty exists about the
human toxicity of the vast majority of
chemicals in widespread use. Increased
epidemiological research (the identification of aetiological agents or risk factors
through population studies), would enable definitive identification of more human toxins. This would also increase the
data set available for validation studies of
test models. Concurrent human sociological or psychological studies may increase
our understanding of factors predisposing
toward risky lifestyle choices.
In some cases, existing social infrastructure can be recruited in support of
such studies. For example, cancer treatment centres could be funded to establish
tumour registries aimed at identifying new
lifestyle, occupational, environmental and
medical carcinogens. Post-marketing surveillance of human pharmaceuticals, with
reporting of adverse side effects, is already required in most jurisdictions, and
should be fully utilised, perhaps through
provision of incentives to participating
physicians, whose available time may be
very limited.

of stresses and strains, and of the effects
on implant movement and fracture probabilities of various mechanical or thermal
loads (Gallas et al., 2005). Such simulations rely on finite element (FE) analysis – an engineering technique. Structures are modelled by subdividing them
into a meshwork of theoretical elements
bounded by nodes. The magnitude at various nodes of effects such as strains and
stresses applied to the structure can then
be computed mathematically. FE analysis
has been widely applied in studies of dental materials, oral and maxillofacial surgery, orthodontics and dental restorations
(Mackerle, 2004).
The use of donated human tissue or cell
lines is appropriate for certain biochemical questions – such as those investigating human cellular receptors. In some
cases surrogate tissues may be used. For
example, mast cells isolated from human
placenta have some features in common
with neurons – including the possession
of a functional receptor for nerve growth
factor, and may therefore be used for appropriate neuropharmacological, neurophysiological and neurotoxicological
studies (Purcell and Atterwill, 1995).
As stated, the ability of hESCs to produce a wide range of differentiated cell
types makes them particularly valuable.
Schrattenholz and Klemm (2007), for example, described models of human neu-

Existing Evidence
Existing
Evidence
Collation
review
Collation and
and review

2.8.3 Additional human
investigation

A wide range of other investigative tools
is available for the non-invasive examination of human beings. To varying degrees,
biomechanical and other bodily systems
and processes may be modelled mathematically, and their behaviour predicted
by computerised simulations (Langley
et al., 2007). For example, the effects of
dental or surgical interventions may be
simulated by incorporation of the biomechanical characteristics of various human tissues within mathematical models.
The structural properties of human tooth,
bone and ligament, and of dental materials such as ceramic and titanium, can be
incorporated into simulations of dental
prosthetic implants, allowing predictions
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rodegenerative diseases based on neurons
derived from hESC precursors. Using
calcium imaging (because various neuropathological processes appear to be associated with altered calcium levels), mitochondrial potential measurements and
Western blots, they demonstrated their
functionality, and further, that the model
reproduced crucial mechanistic aspects
observed during ischaemia and excitotoxicity, that are considered central to some
neurodegenerative diseases.
Anatomical investigations of donated
human cadavers and tissues may be conducted via gross or histological examination, and a variety of imaging techniques
may be used in human volunteer studies,
such as plain or contrast radiographs, ultrasonography, computed tomography,
functional magnetic resonance imaging
(fMRI), and positron emission tomography (PET). Such minimally-invasive
investigative tools may also be applied
within animal studies, thereby achieving
refinement of animal use.
Even the complexities of the human
brain may sometimes be amenable to
such study. Neural activity in various regions of the brain can be correlated with
specific cognitive, physiological or physical activities via fMRI or PET. The functional necessity or redundancy of regions
thereby identified can be investigated
using transcranial magnetic stimulation.
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Applied using a coil, an electromagnetic
field disrupts neurological activity in an
area of interest for tens of milliseconds
or longer, during which period volunteers perform cognitive, visual or other
tasks (Barker et al., 1985; Schriefer et al.,
1988; Langley et al., 2000; Heindl et al.,
2008).
2.9 Integrated toxicity testing
strategies

Toxicity testing protocols utilising tiered
combinations of non-animal assays have
been described, for example by the UK
Department of Health (2000), Worth
and Balls (2002), Knight and colleagues
(2006a), Combes (2007), and Combes
and colleagues (2007). They should include elements appropriate to the individual case, which would normally be
conducted in sequence, as in Figure 1.
Not all testing stages will be necessary
in every case, particularly when positive
toxicity data are obtained in earlier stages. The appropriate level of testing will be
influenced by factors such as production
volumes, human exposure risks, and legislative or regulatory requirements.
Not all appropriate assays will have
been scientifically validated, nor adopted
by regulatory authorities. However, properly collating and examining the more targeted data obtained through such a testing
scheme is likely to yield a weight-of-evidence characterisation for human toxicity
of superior predictivity to that currently
offered by conventional animal-based
assays, such as the traditional rodent bioassay. It may also facilitate greater understanding of mechanisms of toxicity.
3 Conclusions

A definitive review of non-animal research and testing methodologies would
be impossible, in anything less than a series of dedicated volumes. Nevertheless,
it remains clearly apparent from this limited review that a broad range of investigative tools exists, with the potential to
replace animal use within biomedical research and toxicity testing. These include
mechanisms to enhance the sharing and
assessment of existing data prior to conducting further studies; physicochemical
evaluation and computerised modelling,
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including the use of SARs and expert systems; and the use of minimally-sentient
animals from lower phylogenetic orders,
early developmental vertebral stages, microorganisms, and higher plants.
A variety of tissue cultures are available, including immortalised cell lines,
embryonic and adult SCs and organotypic cultures. In vitro assays utilising
bacterial, yeast, protozoal, mammalian or
human cell cultures exist for a wide range
of toxic and other endpoints. These may
be used individually or combined as batteries, and kept static or perfused. Human
hepatocyte cultures and metabolic activation systems may facilitate identification
of metabolic pathways, determination of
metabolites produced, and assessment
of organ-organ interaction. Microarray
technology may allow genetic expression
profiling of toxins, increasing their speed
of detection, well prior to more invasive
endpoints.
Enhanced human clinical trials utilising
microdosing, as well as surrogate human
tissues, advanced imaging modalities and
human epidemiological, sociological, and
psychological studies, may all increase
our understanding of illness aetiology and
pathogenesis, and facilitate the development of safe and effective pharmacologic
interventions.
Non-animal investigative methods
cannot, of course, provide answers to
all questions about humans, particularly
given present technological limitations.
However, the same is certainly true of animal models, which have a more limited
capacity for further development.
However, non-animal models can offer
certain important advantages, when compared to animal use. Particularly when
humans or human tissues are used, such
alternatives may generate faster, cheaper
results, more reliably predictive for humans, and may yield greater insights
into human biochemical processes. Such
considerations are becoming increasingly
important, given the logistical challenges
posed by the high-throughput toxicity
testing requirements of US and EU testing
programmes such as HPV and REACH,
and also, increasing social pressures to
find alternatives to laboratory animal
use, reflected in legislative or regulatory
changes, such as the 7th Amendment to
the EU Cosmetics Directive.

However, despite substantial ongoing progress in the development of nonanimal alternatives, compliance with the
spirit of the 3Rs and, indeed, the letter
of some associated regulations, unfortunately remains poor within some sectors
of government, academia and industry.
Continued reliance on animal models is
understandable when truly required by
regulators for the licensing of drugs and
chemicals. The position of such regulators
themselves appears less justifiable, however. Some apparently “feel more comfortable” with animal data (O’Connor,
1997), or even believe animal tests are
inherently valid, simply because they are
conducted in animals (Balls, 2004). Yet,
such reliance on animal models persists
for historical and cultural reasons, rather
than because they have been demonstrated to be scientifically valid. Animalbased toxicology, at least, indeed appears
to be “frozen in time, using and accepting
the same old animal models again and
again, often without stringent examination of their validity” (Hartung, 2008a;
Leist, 2008b).
In many cases particular alternatives
have been developed and successfully
used at a particular laboratory, but transfer of such technology elsewhere is minimal. Reproducibility and transfer would
be assisted by increased description and
standardisation of methodologies. Journal space is limited, and so Gruber and
Hartung (2004) proposed the establishment of publicly-accessible methodology
databases, which could provide supplementary links to articles – a simple accomplishment, given modern technology.
As Gruber and Hartung observed, however, more fundamental problems appear
to exist. These include incorrect assumptions of the human utility of animal models, and a dearth of interest in exploring
alternatives to animal use. Greater commitment to the development and use of
non-animal alternatives is clearly necessary, to maximise efficiency when meeting the needs of high-throughput toxicity
testing programmes, the ongoing development of human clinical interventions,
and important emerging testing needs,
such as the toxicity testing of nanoparticles, genetically-altered or irradiated
food, and mobile phone radiation – none
of which can be adequately assessed usAltex 25, 3/08
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ing classical animal models (Leist et al.,
2008b).
Several mechanisms could substantially assist this process. Public funds previously spent on animal tests required by
regulators could be redirected into the further development and implementation of
alternatives (Gruber and Hartung, 2004).
Considerably more stringent compliance
with relevant animal welfare legislation
requiring the consideration or use of alternatives could – and should – become
a prerequisite of research funding, ethics
committee approval of experiments, and
publication of results. These measures
would require the education and cooperation of funding agencies, ethics committees and journal editors, about the limitations of animal models, and the potential
of non-animal alternatives. Each of these
measures is eminently achievable. All
that is required is the will to do so.
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